Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
22 hedge funds and large institutions have $1.76M invested in Titan Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
16% less capital invested
Capital invested by funds: $2.1M → $1.76M (-$343K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75.3K |
| 2 |
Renaissance Technologies
New York
|
+$58.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$41.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$4.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$41.8K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$18K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 4 |
BlackRock
New York
|
-$4.18K |
| 5 |
Morgan Stanley
New York
|
-$4.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
27
BNP Paribas Financial Markets
Paris,
France
| $2 | – | – | – |
|
|
WS
28
Wedbush Securities
Los Angeles,
California
| – | -$18K | -4 | Closed |
|
|
TSS
29
Two Sigma Securities
New York
| – | -$16K | -3 | Closed |
|
|
DOA
30
D'Orazio & Associates
Falls Church,
Virginia
| – | -$1K | – | – |
|
TTNP Hedge Fund Activity: Q1 2018 in Review
22 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2018, worth a combined $1.76M — down 16% from $2.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TTNP positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $75.3K. The largest seller was Millennium Management, cutting an estimated $41.8K.
- 22 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2018, up from 21 in Q4 2017.
- Funds reported $1.76M of Titan Pharmaceuticals stock for Q1 2018, down 16% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q1 2018 and 2 closed out, a net change of +1 holder.
- The largest Titan Pharmaceuticals buyer in Q1 2018 was Susquehanna International Group, an estimated $75.3K added.
- The largest Titan Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $41.8K sold.
Based on aggregated 13F filings for Q1 2018.